Management of relapsed/refractory Chronic Lymphocytic Leukemia

por Woyach, Jennifer A.
Publicado 2022

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL

por Rogers, Andrew, Woyach, Jennifer A.
Publicado 2020

Boosting BNT162b2 vaccine efficacy in CLL

por Bhat, Seema A., Woyach, Jennifer A.
Publicado 2022

Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts

por Gregory, Thomas, Ngankeu, Apollinaire, Orwick, Shelley, Kautto, Esko A, Woyach, Jennifer A, Byrd, John C, Blachly, James S
Publicado 2020

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL

por Yano, Max, Nunes, Jessica, Mo, Xiaokui, Rogers, Kerry A., Woyach, Jennifer A., Byrd, John C., Muthusamy, Natarajan
Publicado 2022

Incidence and survival of hematological cancers among adults ages ≥75 years

por Krok‐Schoen, Jessica L., Fisher, James L., Stephens, Julie A., Mims, Alice, Ayyappan, Sabarish, Woyach, Jennifer A., Rosko, Ashley E.
Publicado 2018

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019

por Kittai, Adam S., Huang, Ying, Bhat, Seema A., Paskett, Electra D., Rogers, Kerry A., Barrientos, Jacqueline C., Fisher, James L., Woyach, Jennifer A.
Publicado 2022

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

por Woyach, Jennifer A, Lin, Thomas S, Lucas, Margaret S, Heerema, Nyla, Moran, Mollie E., Cheney, Carolyn, Lucas, David M., Wei, Lai, Caligiuri, Michael A., Byrd, John C.
Publicado 2009

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

por Muhowski, Elizabeth M., Ravikrishnan, Janani, Gordon, Britten, Yu, Lianbo, Misra, Shrilekha, Walker, Brandi, Eathiraj, Sudharshan, Sampath, Deepa, Rogers, Kerry A., Byrd, John C., Woyach, Jennifer A.
Publicado 2022

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

por Woyach, Jennifer A., Barr, Paul M., Kipps, Thomas J., Barrientos, Jacqueline C., Ahn, Inhye E., Ghia, Paolo, Girardi, Vincent, Hsu, Emily, Jermain, Mandy, Burger, Jan A.
Publicado 2023

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

por Hyak, Jonathan M., Huang, Ying, Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Byrd, John C., Kittai, Adam S., Jones, Dan, Miller, Cecelia R., Woyach, Jennifer A.
Publicado 2022

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition

por Eisenmann, Eric D., Fu, Qiang, Muhowski, Elizabeth M., Jin, Yan, Uddin, Muhammad Erfan, Garrison, Dominique A., Weber, Robert H., Woyach, Jennifer A., Byrd, John C., Sparreboom, Alex, Baker, Sharyn D.
Publicado 2021

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia

por Guinn, Daphne, Lehman, Amy, Fabian, Catherine, Yu, Lianbo, Maddocks, Kami, Andritsos, Leslie A., Jones, Jeffrey A., Flynn, Joseph M., Jaglowski, Samantha M., Woyach, Jennifer A., Byrd, John C., Johnson, Amy J.
Publicado 2017

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six...

por Gopalakrishnan, Sathej, Menon, Rajeev, Suleiman, Ahmed A., Kater, Arnon P., Stilgenbauer, Stephan, Seymour, John F., Chyla, Brenda, Lu, Tong, Young Kim, Su, Roberts, Andrew W., Woyach, Jennifer A., Mensing, Sven, Salem, Ahmed Hamed
Publicado 2023

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

por Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Publicado 2021

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol

por Blum, Kristie A., Ruppert, Amy S., Woyach, Jennifer A., Jones, Jeffrey A., Andritsos, Leslie, Flynn, Joseph M., Rovin, Brad, Villalona-Calero, Miguel, Ji, Jia, Phelps, Mitchell, Johnson, Amy J., Grever, Michael R., Byrd, John C.
Publicado 2011

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

por Woyach, Jennifer A., Ghia, Paolo, Byrd, John C., Ahn, Inhye E., Moreno, Carol, O'Brien, Susan M., Jones, Daniel, Cheung, Leo W.K., Chong, Elizabeth, Kwei, Kevin, Dean, James P., James, Danelle F., Wiestner, Adrian
Publicado 2023

Optimizing extracellular vesicles’ isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant

por Elgamal, Sara, Cocucci, Emanuele, Sass, Ellen J., Mo, Xiaokui M., Blissett, Angela R., Calomeni, Edward P., Rogers, Kerry A., Woyach, Jennifer A., Bhat, Seema A., Muthusamy, Natarajan, Johnson, Amy J., Larkin, Karilyn T., Byrd, John C.
Publicado 2021

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy

por Yano, Max, Sharpe, Chia, Lance, J. Rachel, Ravikrishnan, Janani, Zapolnik, Kevan, Mo, Xiaokui, Woyach, Jennifer A., Sampath, Deepa, Kittai, Adam S., Vasu, Sumithira, Bhat, Seema, Rogers, Kerry A., Lee, Dean A., Muthusamy, Natarajan, Byrd, John C.
Publicado 2022

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

por Bond, David A, Huang, Ying, Fisher, James L, Ruppert, Amy S, Owen, Dwight H, Bertino, Erin M, Rogers, Kerry A, Bhat, Seema A, Grever, Michael R, Jaglowski, Samantha M, Maddocks, Kami J, Byrd, John C, Woyach, Jennifer A
Publicado 2020